Literature DB >> 10101020

Reduction of calcineurin activity in brain by antisense oligonucleotides leads to persistent phosphorylation of tau protein at Thr181 and Thr231.

T D Garver1, R L Kincaid, R A Conn, M L Billingsley.   

Abstract

Phosphorylation of tau protein promotes stability of the axonal cytoskeleton; aberrant tau phosphorylation is implicated in the biogenesis of paired helical filaments (PHF) seen in Alzheimer's disease. Protein kinases and phosphatases that modulate tau phosphorylation have been identified using in vitro techniques; however, the role of these enzymes in vivo has not been determined. We used intraventricular infusions of antisense oligodeoxynucleotides (ODNs) directed against the major brain isoforms of the Ca2+/calmodulin-dependent phosphatase calcineurin to determine how reduced activity of this enzyme would affect tau dephosphorylation. Five-day infusions of antisense ODNs (5 and 10 nmol/day) in rats decreased immunoreactive levels and activity of calcineurin throughout the brain; sense ODNs, scrambled ODNs, and infusion vehicle alone had no effect. When neocortical slices were prepared from antisense ODN-treated rats and incubated for 1 to 2 h in vitro, tau protein remained phosphorylated as determined by using the phosphorylation-sensitive monoclonal antibodies AT-180 (Thr231) and AT-270 (Thr181). In contrast, AT-180 and AT-270 sites were completely dephosphorylated during incubation of neocortical slices from vehicle-infused controls and sense ODN-treated rats. Neocortical slices from antisense-treated rats were incubated with the phosphatase inhibitors okadaic acid (100 nM; 10 microM) and FK-520 (5 microM); these preparations showed enhanced tau phosphorylation, consistent with a significant loss of calcineurin activity. Thus, we conclude that phosphorylation of at least two sites on tau protein, namely, Thr181 and Thr231, is regulated by calcineurin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10101020

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Calcineurin A-alpha but not A-beta is required for normal kidney development and function.

Authors:  Jennifer L Gooch; Juan J Toro; Rebecca L Guler; Jeffrey L Barnes
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 2.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

Review 3.  Protein phosphatases and Alzheimer's disease.

Authors:  Steven P Braithwaite; Jeffry B Stock; Paul J Lombroso; Angus C Nairn
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

4.  PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau.

Authors:  A Rahman; I Grundke-Iqbal; K Iqbal
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

5.  Depotentiation of Long-Term Potentiation Is Associated with Epitope-Specific Tau Hyper-/Hypophosphorylation in the Hippocampus of Adult Rats.

Authors:  Ercan Babür; Burak Tan; Sumeyra Delibaş; Marwa Yousef; Nurcan Dursun; Cem Süer
Journal:  J Mol Neurosci       Date:  2018-11-29       Impact factor: 3.444

6.  Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.

Authors:  Min-Su Jung; Jung-Hwa Park; Young Shin Ryu; Sun-Hee Choi; Song-Hee Yoon; Mi-Yang Kwen; Ji Youn Oh; Woo-Joo Song; Sul-Hee Chung
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

7.  Do RCAN1 proteins link chronic stress with neurodegeneration?

Authors:  Gennady Ermak; Melanie A Pritchard; Sladjana Dronjak; Brenda Niu; Kelvin J A Davies
Journal:  FASEB J       Date:  2011-06-16       Impact factor: 5.191

Review 8.  Potential role of calcineurin in pathogenic conditions.

Authors:  Khaliq Kurji; Rajendra K Sharma
Journal:  Mol Cell Biochem       Date:  2009-12-05       Impact factor: 3.396

9.  SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Authors:  Carlos Cruchaga; John S K Kauwe; Kevin Mayo; Noah Spiegel; Sarah Bertelsen; Petra Nowotny; Aarti R Shah; Richard Abraham; Paul Hollingworth; Denise Harold; Michael M Owen; Julie Williams; Simon Lovestone; Elaine R Peskind; Ge Li; James B Leverenz; Douglas Galasko; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  PLoS Genet       Date:  2010-09-16       Impact factor: 5.917

10.  Dephosphorylation of tau protein by calcineurin triturated into neural living cells.

Authors:  Qun Wei; Max Holzer; Martina K Brueckner; Yu Liu; Thomas Arendt
Journal:  Cell Mol Neurobiol       Date:  2002-02       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.